Transcend Capital Advisors LLC Has $224,000 Position in Humana Inc. $HUM

Transcend Capital Advisors LLC cut its position in Humana Inc. (NYSE:HUM) by 31.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 916 shares of the insurance provider’s stock after selling 414 shares during the quarter. Transcend Capital Advisors LLC’s holdings in Humana were worth $224,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Humana by 16.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,136,538 shares of the insurance provider’s stock worth $300,728,000 after purchasing an additional 158,528 shares in the last quarter. Focus Partners Wealth increased its position in Humana by 104.2% during the 1st quarter. Focus Partners Wealth now owns 6,429 shares of the insurance provider’s stock worth $1,701,000 after purchasing an additional 3,281 shares in the last quarter. Envestnet Asset Management Inc. increased its position in Humana by 2.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider’s stock worth $33,256,000 after purchasing an additional 2,950 shares in the last quarter. Circle Wealth Management LLC acquired a new position in Humana during the 1st quarter worth approximately $425,000. Finally, Arizona State Retirement System increased its position in Humana by 3.4% during the 1st quarter. Arizona State Retirement System now owns 35,337 shares of the insurance provider’s stock worth $9,350,000 after purchasing an additional 1,165 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Trading Down 2.4%

NYSE:HUM opened at $285.78 on Friday. The firm’s fifty day moving average is $281.78 and its 200-day moving average is $259.04. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. Humana Inc. has a 52 week low of $206.87 and a 52 week high of $315.35. The firm has a market cap of $34.37 billion, a P/E ratio of 21.93, a P/E/G ratio of 1.71 and a beta of 0.42.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. During the same period in the prior year, the company posted $6.96 earnings per share. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. Equities analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Friday, December 26th. Humana’s dividend payout ratio is currently 27.17%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Morgan Stanley lowered their price objective on shares of Humana from $290.00 to $277.00 and set an “equal weight” rating for the company in a research report on Thursday, July 31st. Wells Fargo & Company upped their price target on shares of Humana from $344.00 to $347.00 and gave the company an “overweight” rating in a research report on Tuesday, October 7th. Truist Financial set a $300.00 price target on shares of Humana in a research report on Tuesday, October 14th. Wall Street Zen cut shares of Humana from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Finally, Wolfe Research upped their price target on shares of Humana from $283.00 to $313.00 and gave the company an “outperform” rating in a research report on Monday, October 6th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $297.58.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.